Claims
- 1. A pressure sensitive adhesive composition for the transdermal administration of a therapeutic agent comprising, by weight:
- (a) 0.1-30% of a therapeutic agent,
- (b) 30-90% of a hydrophobic pressure sensitive adhesive,
- (c) 1-40% of a permeation enhancer capable of plasticizing the hydrophobic pressure sensitive adhesive, said permeation enhancer comprising lauryl acetate and a monoglyceride.
- 2. A composition according to claim 1 wherein the composition is a hot melt pressure sensitive adhesive.
- 3. A composition according to claim 2 comprising a viscosity within the range of 10.sup.3 -10.sup.7 Poise.
- 4. A composition according to claim 3 comprising a viscosity within the range of 2.times.10.sup.5 -10.sup.6 Poise.
- 5. A composition according to claim 1 wherein the composition comprises 1-30% glycerol monolaurate and 1-30% by weight lauryl acetate.
- 6. A composition according to claim 1 further comprising 1-30% by weight of a water absorbing polymer.
- 7. A composition according to claim 6 wherein the water absorbing polymer is selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol, and polyaminoacrvlates.
- 8. A device for the transdermal administration of a therapeutic agent at a therapeutically effective rate comprising:
- (a) a backing layer, and
- (b) an agent reservoir matrix on the skin contacting surface of the backing layer comprising a polymeric blend comprising, by weight:
- (i) 40-90% of a hydrophobic pressure sensitive adhesive,
- (ii) 0.1-30% therapeutic agent, and
- (iii) a permeation enhancer comprising 1-30% of a monoglyceride and 1-30% lauryl acetate.
- 9. A device according to claim 8, wherein the monoglyceride is glycerol monolaurate.
- 10. A device according to claim 8 wherein the agent reservoir further comprises 1-30% of a water absorbing polymer.
- 11. A device according to claim 10 wherein the water absorbing polymer is selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol, and polyaminoacrylates.
- 12. A device according to claim 11 wherein the water absorbing polymer is polyvinyl pyrrolidone.
- 13. A device according to claim 11 wherein the hydrophobic pressure sensitive adhesive is a polysiloxane adhesive.
- 14. A device according to claim 9 wherein the therapeutic agent is selected from the group consisting of testosterone, progesterone, nandrolone, and estradiol.
- 15. A device according to claim 14 wherein the therapeutic agent is testosterone.
- 16. A device according to claim 15 wherein the reservoir matrix comprises testosterone at or above saturation.
- 17. A device according to claim 10 comprising 60-90% polysiloxane adhesive, 5-25% polyvinyl pyrrolidone, 1-15% testosterone, 1-20% glycerol monolaurate, and 1-20% lauryl acetate.
- 18. A device according to claim 8 wherein the lauryl acetate is at least 97% pure.
- 19. A composition according to claim 1 wherein the hydrophobic pressure sensitive adhesive comprises a polysiloxane adhesive.
RELATED APPLICATIONS
This application is a continuation-in-part of Ser. No. 08/481,549, now U.S. Pat. No. 5,785,991, filed Jun. 7, 1995, assigned to ALZA Corporation, for which the benefit of the earlier filing date is claimed.
US Referenced Citations (53)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0272918 |
Jun 1988 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
481549 |
Jun 1995 |
|